PRV-3279 is a Monoclonal Antibody owned by Provention Bio, and is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing.
PRV-3279 (MGD-010) is a bi-specific monoclonal antibody acts as CD79B antagonist and CD32B agonist. DART molecule targets two receptors with a single molecule, and also promotes the interaction of these two receptors to interrupt the autoimmune response. MGD-010 capable of co-ligating the activating and the inhibitory receptors on the B-cell surface, resulting in reduced BCR-induced calcium mobilization and phosphorylation of selected signaling molecules. These biochemical changes correlated with inhibition of B-cell proliferation and Ig secretion upon B-cell activation. The drug candidate blocks the activation of those cells that produce the pathogenic antibodies and support the autoimmune process.
The revenue for PRV-3279 is expected to reach a total of $59m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PRV-3279 NPV Report.
PRV-3279 (MGD-010) is under development for the treatment of autoimmune diseases such as systemic lupus erythematosus, prevention of immunogenicity and Pompe disease. The therapeutic candidate is administered intravenously as an infusion. It is a bi-specific bivalent antibody based on Dual-Affinity Re-Targeting (DART) technology platform. This DART scaffold is used to couple an Fv specific for the inhibitory receptor, CD32B, with an Fv specific for the Ig-beta component (CD79B) of the B-cell antigen receptor (BCR). The therapeutic candidate specifically targets B-lymphocytes to treat autoimmune diseases.
Provention Bio Overview
Provention Bio (Provention), is a clinical-stage biopharmaceutical company. It develops novel therapeutics for intercepting and preventing immune-mediated diseases. The company’s pipeline product portfolio includes PRV-031 teplizumab for the treatment of type one diabetes (T1D); PRV-015 is an anti-IL-15 monoclonal antibody for gluten-free diet non-responsive celiac disease (NRCD). It also develops PRV-3279 for preventing immunogenicity and SLE; PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine developed for treating type one diabetes (T1D). Provention has licensing and co-development agreement with pharmaceutical and biotherapeutic industries includes Vactech Oy, Amgen Inc and MacroGenics Inc. Provention is headqutered in Red Bank, New Jersey, the US.
The company reported revenues of (US Dollars) US$1.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$115.6 million in FY2021, compared to an operating loss of US$99.7 million in FY2020. The net loss of the company was US$114.4 million in FY2021, compared to a net loss of US$98.6 million in FY2020. The company reported revenues of US$0.8 million for the third quarter ended September 2022, an increase of 1.3% over the previous quarter.
Quick View – PRV-3279
|Highest Development Stage|